Adding a second monoclonal antibody drug to chemotherapy looks promising for treatment of diffuse large B-cell lymphoma, according to researchers working with the North Central Cancer Treatment Group.
Adding a second monoclonal antibody drug to chemotherapy looks promising for treatment of diffuse large B-cell lymphoma, according to researchers working with the North Central Cancer Treatment Group.